NCT03630926View on ClinicalTrials.gov

Evaluation of the NV-VPAC1 Prostate Cancer (PCa) Urine Diagnostic Test in Subjects With Biopsy-confirmed Prostate Cancer, Benign Prostatic Hypertrophy, or Bladder/Kidney Stones.

UnknownOBSERVATIONAL
Enrollment

45

Participants

Timeline

Start Date

October 16, 2018

Primary Completion Date

August 31, 2019

Study Completion Date

December 31, 2019

Conditions
Prostate CancerBenign Prostatic HypertrophyBladder StonesKidney Stones
Interventions
DIAGNOSTIC_TEST

NV-VPAC1 PCa Urine Diagnostic Test

The NV-VPAC1 PCa Urine Diagnostic Test is intended for use by clinicians to detect the presence of prostate cancer cells shed in voided urine of men at risk for prostate cancer.

Trial Locations (1)

84107

Intermountain Medical Center, Murray

Sponsors

Collaborators (1)

NuView Diagnostics
All Listed Sponsors
lead

Intermountain Health Care, Inc.

OTHER

collaborator

NuView Diagnostics

UNKNOWN

NCT03630926 - Evaluation of the NV-VPAC1 Prostate Cancer (PCa) Urine Diagnostic Test in Subjects With Biopsy-confirmed Prostate Cancer, Benign Prostatic Hypertrophy, or Bladder/Kidney Stones. | Biotech Hunter | Biotech Hunter